Brain tumors are common, requiring general medical providers to have a basic understanding of their diagnosis and management. The most prevalent brain tumors are intracranial metastases from systemic cancers, meningiomas, and gliomas, specifically, glioblastoma. Central nervous system metastases may occur anywhere along the neuroaxis, and require complex multidisciplinary care with neurosurgery, radiation oncology, and medical oncology. Meningiomas are tumors of the meninges, mostly benign and often managed by surgical resection, with radiation therapy and chemotherapy reserved for high-risk or refractory disease. Glioblastoma is the most common and aggressive malignant primary brain tumor, with a limited response to standard-of-care concurrent chemoradiation. This review addresses the specific contributions of nuclear medicine techniques, and especially positron emission tomography (PET), for diagnosis and management of brain tumors. F-Fluorodeoxyglucose PET has particular strengths in predicting prognosis and differentiating cerebral lymphoma from nonmalignant lesions. Amino acid tracers including C-methionine, F-fluoroethyltyrosine, and F-L-3,4-dihydroxyphenylalanine provide high sensitivity, which is most useful for detecting recurrent or residual gliomas, including most low-grade gliomas. They also play an increasing role for planning and monitoring of therapy. F-fluorothymidine can only be used in tumors with absent or broken blood–brain barrier and has potential for tumor grading and monitoring of therapy. Ligands for somatostatin receptors are of particular interest in pituitary adenomas and meningiomas. Tracers to image neovascularization, hypoxia, and phospholipid synthesis are under investigation for potential clinical use.
Cite this article:
Kanchan R. Pagar, Mukta R. Mahale. A Review on Brain Tumour, Etiology and Treatment. Asian Journal of Pharmaceutical Research. 2023; 13(1):51-4. doi: 10.52711/2231-5691.2023.00010
Kanchan R. Pagar, Mukta R. Mahale. A Review on Brain Tumour, Etiology and Treatment. Asian Journal of Pharmaceutical Research. 2023; 13(1):51-4. doi: 10.52711/2231-5691.2023.00010 Available on: https://asianjpr.com/AbstractView.aspx?PID=2023-13-1-10